acetylgalactosamine has been researched along with Chronic Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banyai, T; Campbell, F; Chen, S; Dalekos, GN; Deeg, M; Deng, Y; Goulis, I; Hamatake, R; Han, K; Horvath, G; Huang, M; Jilma, B; Lahiri, S; Leivers, M; Manolakopoulos, S; Papatheodoridis, G; Theodore, D | 1 |
| Beuers, U; Blem, J; de Vree, JM; Gibson, NW; Grint, P; Grundy, J; Hadi, S; Harbers, M; Huang, M; Kootstra, NA; Liu, K; Molenkamp, R; Neben, S; Patick, AK; Pavlicek, A; Reesink, HW; Rietdijk, S; Schinkel, J; Stelma, F; van der Ree, MH; van der Valk, M; van der Veer, E; van Nuenen, AC; Willemse, S | 1 |
2 trial(s) available for acetylgalactosamine and Chronic Hepatitis C
| Article | Year |
|---|---|
Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants.
Topics: Acetylgalactosamine; Adult; Antiviral Agents; Benzofurans; Double-Blind Method; Healthy Volunteers; Hepatitis C, Chronic; Humans; Male; Oligonucleotides; Treatment Outcome | 2020 |
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
Topics: Acetylgalactosamine; Cohort Studies; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Male; MicroRNAs; Middle Aged; Oligonucleotides; Viral Load | 2017 |